Verrica completes enrolment in Phase III trial of Ycanth

Phase 3YcanthPositive

AI Analysis

Summary

Verrica Pharmaceuticals has completed patient enrolment in its Phase III COVE-2 trial evaluating Ycanth for the treatment of common warts. This milestone marks progression toward potential regulatory submission for the investigational therapy.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Patient enrolment completed in COVE-2 trial

Importance:6/10

Sentiment:

0.50

Phase 3trial enrollmentYcanthcommon wartsVerrica

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 28, 2026 9:47 AM

Read Original